Global Clinical Trials (GCT), renowned for its expertise in epilepsy research, has secured a pivotal study contract from a leading Korean pharmaceutical company. The study, focusing on primary generalized tonic-clonic seizures, is set to be conducted across 21 sites in Georgia, India, and Ukraine.

With GCT’s extensive background in epilepsy research and its role as a Contract Research Organization (CRO), the company is poised to provide support throughout the study’s duration, from regulatory to patient recruitment, monitoring, logistics and PM.

For more information about GCT’s expertise in epilepsy and other Central Nervous System indications, please contact us at